Innate immune induction and influenza protection elicited by a response-selective agonist of human C5a

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Sanderson, Sam D ^a   Thoman, Marilyn L ^b,c   Kis, Kornelia ^c   Virts, Elizabeth L ^b,c   Herrera, Edgar B ^c   Widmann, Stephanie ^d   Sepulveda, Homero ^d   Phillips, Joy A ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b SIDNEY KIMMEL CANCER CENTER   (United States)

^c SAN DIEGO STATE UNIVERSITY   (United States)

^d BD BIOSCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A; CXCL1 CHEMOKINE; EP 67; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTECTIVE AGENT; TUMOR NECROSIS FACTOR; TYROSYLSERYLPHENYLALANYLLYSYLASPARTYLMETHIONYLPROLYL(N METHYL LEUCINE)DEXTRO ALANYLARGININE; UNCLASSIFIED DRUG;

AERATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; INFECTION PREVENTION; INFLUENZA A; INNATE IMMUNITY; LUNG LAVAGE; MALE; MORTALITY; MOUSE; NATURAL KILLER T CELL; NEUTROPHIL; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE;

ANIMALS; ANTIGEN-PRESENTING CELLS; CHEMOKINES; COMPLEMENT C5A; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; INSUFFLATION; KINETICS; LUNG; MACROPHAGES, ALVEOLAR; MALE; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES;

BACTERIA (MICROORGANISMS); MURINAE; MUS;

EID: 84863649352     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040303     Document Type: Article

References (70)

1. Kohl J, (2006) The role of complement in danger sensing and transmission. Immunol Res 34: 157-176.
2. Kohlmeier JE, Woodland DL, (2009) Immunity to respiratory viruses. Annu Rev Immunol 27: 61-82.
3. Parker D, Prince A, (2011) Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol 45: 189-201.
4. Goodman MG, Chenoweth DE, Weigle WO, (1982) Potentiation of the primary humoral immune response in vitro by C5a anaphylatoxin. J Immunol 129: 70-75.
5. Morgan EL, Thoman ML, Weigle WO, Hugli TE, (1983) Anaphylatoxin-mediated regulation of the immune response. II. C5a-mediated enhancement of human humoral and T cell-mediated immune responses. J Immunol 130: 1257-1261.
6. Hugli TE, Marceau F, Lundberg C, (1987) Effects of complement fragments on pulmonary and vascular smooth muscle. Am Rev Respir Dis 135: S9-13.
7. Hugli TE, Muller-Eberhard HJ, (1978) Anaphylatoxins: C3a and C5a. Adv Immunol 26: 1-53.
8. Montz H, Fuhrmann A, Schulze M, Gotze O, (1990) Regulation of the human autologous T cell proliferation by endogenously generated C5a. Cell Immunol 127: 337-351.
9. Hopken UE, Lu B, Gerard NP, Gerard C, (1996) The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 383: 86-89.
10. Kim AH, Dimitriou ID, Holland MC, Mastellos D, Mueller YM, et al. (2004) Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses. J Immunol 173: 2524-2529.
11. Moulton RA, Mashruwala MA, Smith AK, Lindsey DR, Wetsel RA, et al. (2007) Complement C5a anaphylatoxin is an innate determinant of dendritic cell-induced Th1 immunity to Mycobacterium bovis BCG infection in mice. J Leukoc Biol 82: 956-967.
12. Strainic MG, Liu J, Huang D, An F, Lalli PN, et al. (2008) Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 28: 425-435.
13. Hicks JT, Ennis FA, Kim E, Verbonitz M, (1978) The importance of an intact complement pathway in recovery from a primary viral infection: influenza in decomplemented and in C5-deficient mice. J Immunol 121: 1437-1445.
14. Bjornson AB, Mellencamp MA, Schiff GM, (1991) Complement is activated in the upper respiratory tract during influenza virus infection. Am Rev Respir Dis 143: 1062-1066.
15. Diaz-Mitoma F, Alvarez-Maya I, Dabrowski A, Jaffey J, Frost R, et al. (2004) Transcriptional analysis of human peripheral blood mononuclear cells after influenza immunization. J Clin Virol 31: 100-112.
16. Suresh M, Molina H, Salvato MS, Mastellos D, Lambris JD, et al. (2003) Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J Immunol 170: 788-794.
17. Finch AM, Vogen SM, Sherman SA, Kirnarsky L, Taylor SM, et al. (1997) Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity. J Med Chem 40: 877-884.
18. Tempero RM, Hollingsworth MA, Burdick MD, Finch AM, Taylor SM, et al. (1997) Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin. J Immunol 158: 1377-1382.
19. Vogen SM, Paczkowski NJ, Kirnarsky L, Short A, Whitmore JB, et al. (2001) Differential activities of decapeptide agonists of human C5a: the conformational effects of backbone N-methylation. Int Immunopharmacol 1: 2151-2162.
20. Vogen SM, Prakash O, Kirnarsky L, Sanderson SD, Sherman SA, (1999) Determination of structural elements related to the biological activities of a potent decapeptide agonist of human C5a anaphylatoxin. J Pept Res 54: 74-84.
21. Buchner RR, Vogen SM, Fischer W, Thoman ML, Sanderson SD, et al. (1997) Anti-human kappa opioid receptor antibodies: characterization of site-directed neutralizing antibodies specific for a peptide kappa R(33-52) derived from the predicted amino terminal region of the human kappa receptor. J Immunol 158: 1670-1680.
22. Ulrich JT, Cieplak W, Paczkowski NJ, Taylor SM, Sanderson SD, (2000) Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant. J Immunol 164: 5492-5498.
23. Sanderson SD, Cheruku SR, Padmanilayam MP, Vennerstrom JL, Thiele GM, et al. (2003) Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol 3: 137-146.
24. Hegde GV, Meyers-Clark E, Joshi SS, Sanderson SD, (2008) A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cells. Int Immunopharmacol 8: 819-827.
25. Duryee MJ, Bevins RA, Reichel CM, Murray JE, Dong Y, et al. (2009) Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine 27: 2981-2988.
26. Morgan EL, Morgan BN, Stein EA, Virts EL, Thoman ML, et al. (2009) Enhancement of in vivo and in vitro immune functions by a conformationally-biased, response-selective agonist of human C5a: Implications for a novel adjuvant in vaccine development. Vaccine 28: 463-469.
27. Morgan EL, Thoman ML, Sanderson SD, Phillips JA, (2010) A novel adjuvant for vaccine development in the aged. Vaccine 28: 8275-8279.
28. Sheen TR, Cavaco CK, Ebrahimi CM, Thoman ML, Sanderson SD, et al. (2011) Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide. Vaccine 30(1): 9-13.
29. van der Laan JW, Herberts C, Lambkin-Williams R, Boyers A, Mann AJ, et al. (2008) Animal models in influenza vaccine testing. Expert Rev Vaccines 7: 783-793.
30. Taylor SM, Sherman SA, Kirnarsky L, Sanderson SD, (2001) Development of response-selective agonists of human C5a anaphylatoxin: conformational, biological, and therapeutic considerations. Curr Med Chem 8: 675-684.
31. Spackman E, Senne DA, Myers TJ, Bulaga LL, Garber LP, et al. (2002) Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes. J Clin Microbiol 40: 3256-3260.
32. Cottey R, Rowe CA, Bender BS, (2001) Influenza Virus. Current Protocols in Immunology. 42: 19.11.1-19.11.32.
33. Morgan E, Varro R, Sepulveda H, Ember JA, Apgar J, et al. (2004) Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol 110: 252-266.
34. DeForge LE, Shih DH, Kennedy D, Totpal K, Chuntharapai A, et al. (2007) Species-dependent serum interference in a sandwich ELISA for Apo2L/TRAIL. J Immunol Methods 320: 58-69.
35. Ernst D, (2003) Techniques for Immune Function Analysis: Application Handbook. San Diego: BD Biosciences.
36. Karachunski PI, Ostlie NS, Monfardini C, Conti-Fine BM, (2000) Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J Immunol 164: 5236-5244.
37. Lin KL, Suzuki Y, Nakano H, Ramsburg E, Gunn MD, (2008) CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J Immunol 180: 2562-2572.
38. von Garnier C, Filgueira L, Wikstrom M, Smith M, Thomas JA, et al. (2005) Anatomical location determines the distribution and function of dendritic cells and other APCs in the respiratory tract. J Immunol 175: 1609-1618.
39. Chelen CJ, Fang Y, Freeman GJ, Secrist H, Marshall JD, et al. (1995) Human alveolar macrophages present antigen ineffectively due to defective expression of B7 costimulatory cell surface molecules. J Clin Invest 95: 1415-1421.
40. Dawson TC, Beck MA, Kuziel WA, Henderson F, Maeda N, (2000) Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol 156: 1951-1959.
41. Fernandez-Sesma A, Marukian S, Ebersole BJ, Kaminski D, Park MS, et al. (2006) Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol 80: 6295-6304.
42. Graef KM, Vreede FT, Lau YF, McCall AW, Carr SM, et al. (2010) The PB2 subunit of the influenza virus RNA polymerase affects virulence by interacting with the mitochondrial antiviral signaling protein and inhibiting expression of beta interferon. J Virol 84: 8433-8445.
43. Varga ZT, Ramos I, Hai R, Schmolke M, Garcia-Sastre A, et al. (2011) The influenza virus protein PB1-F2 inhibits the induction of type i interferon at the level of the MAVS adaptor protein. PLoS Pathog 7: e1002067.
44. Glasgow LA, Fischbach J, Bryant SM, Kern ER, (1977) Immunomodulation of host resistance to experimental viral infections in mice: effects of Corynebacterium acnes, Corynebacterium parvum, and Bacille calmette-guerin. J Infect Dis 135: 763-770.
45. Spencer JC, Ganguly R, Waldman RH, (1977) Nonspecific protection of mice against influenza virus infection by local or systemic immunization with Bacille Calmette-Guerin. J Infect Dis 136: 171-175.
46. Guo RF, Ward PA, (2005) Role of C5a in inflammatory responses. Annu Rev Immunol 23: 821-852.
47. Manthey HD, Woodruff TM, Taylor SM, Monk PN, (2009) Complement component 5a (C5a). Int J Biochem Cell Biol 41: 2114-2117.
48. Phillips JA, Morgan EL, Dong Y, Cole GT, McMahan C, et al. (2009) Single-Step Conjugation of Bioactive Peptides to Proteins via a Self-Contained Succinimidyl Bis-Arylhydrazone. Bioconjug Chem 20: 1950-1957.
49. Seo SH, Webster RG, (2002) Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J Virol 76: 1071-1076.
50. Van Reeth K, (2000) Cytokines in the pathogenesis of influenza. Vet Microbiol 74: 109-116.
51. Buchweitz JP, Harkema JR, Kaminski NE, (2007) Time-dependent airway epithelial and inflammatory cell responses induced by influenza virus A/PR/8/34 in C57BL/6 mice. Toxicol Pathol 35: 424-435.
52. Matsukura S, Kokubu F, Noda H, Tokunaga H, Adachi M, (1996) Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells, NCI-H292, induced by influenza virus A. J Allergy Clin Immunol 98: 1080-1087.
53. Huang FF, Barnes PF, Feng Y, Donis R, Chroneos ZC, et al. (2011) GM-CSF in the lung protects against lethal influenza infection. Am J Respir Crit Care Med 184: 259-268.
54. Dranoff G, Crawford AD, Sadelain M, Ream B, Rashid A, et al. (1994) Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 264: 713-716.
55. Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, et al. (2009) Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 119: 1910-1920.
56. Kumar V, Sharma A, (2010) Neutrophils: Cinderella of innate immune system. Int Immunopharmacol 10: 1325-1334.
57. Fujisawa H, Tsuru S, Taniguchi M, Zinnaka Y, Nomoto K, (1987) Protective mechanisms against pulmonary infection with influenza virus. I. Relative contribution of polymorphonuclear leukocytes and of alveolar macrophages to protection during the early phase of intranasal infection. J Gen Virol 68 (Pt 2): 425-432.
58. Tumpey TM, Garcia-Sastre A, Taubenberger JK, Palese P, Swayne DE, et al. (2005) Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J Virol 79: 14933-14944.
59. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, et al. (2000) The neutrophil as a cellular source of chemokines. Immunol Rev 177: 195-203.
60. Culley FJ, (2009) Natural killer cells in infection and inflammation of the lung. Immunology 128: 151-163.
61. Floreani AA, Heires AJ, Welniak LA, Miller-Lindholm A, Clark-Pierce L, et al. (1998) Expression of receptors for C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke. J Immunol 160: 5073-5081.
62. Piqueras B, Connolly J, Freitas H, Palucka AK, Banchereau J, (2006) Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood 107: 2613-2618.
63. Jones SA, (2005) Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 175: 3463-3468.
64. Sanders CJ, Doherty PC, Thomas PG, (2011) Respiratory epithelial cells in innate immunity to influenza virus infection. Cell Tissue Res 343: 13-21.
65. Tamura S, Kurata T, (2004) Defense mechanisms against influenza virus infection in the respiratory tract mucosa. Jpn J Infect Dis 57: 236-247.
66. Moscona A, (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353: 1363-1373.
67. Democratis J, Pareek M, Stephenson I, (2006) Use of neuraminidase inhibitors to combat pandemic influenza. J Antimicrob Chemother 58: 911-915.
68. Wang K, Shun-Shin M, Gill P, Perera R, Harnden A, (2012) Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst Rev 1: CD002744.
69. Balkovic ES, Florack JA, Six HR, (1987) Immunoglobulin G subclass antibody responses of mice to influenza virus antigens given in different forms. Antiviral Res 8: 151-160.
70. Scholtissek C, Muller K, (1991) Failure to obtain drug-resistant variants of influenza virus after treatment with inhibiting doses of 3-deazaadenosine and H7. Arch Virol 119: 111-118.